How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
56
IDXX Quote, Financials, Valuation and Earnings
Last price:
$676.37
Seasonality move
:
3.65%
Day range:
$679.32 - $694.70
52-week range:
$356.14 - $769.98
Dividend yield:
0%
P/E ratio:
54.52x
P/S ratio:
13.46x
P/B ratio:
35.18x
Volume:
426.4K
Avg. volume:
483.1K
1-year change:
64.59%
Market cap:
$54.9B
Revenue:
$3.9B
EPS (TTM):
$12.61
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IDXX
IDEXX Laboratories, Inc.
|
$1.1B | $2.94 | 10.4% | 16.41% | $766.00 |
|
ISRG
Intuitive Surgical, Inc.
|
$2.8B | $2.27 | 16.35% | 10.81% | $611.82 |
|
LLY
Eli Lilly & Co.
|
$18B | $6.95 | 35.51% | 147.92% | $1,133.93 |
|
MRNA
Moderna, Inc.
|
$620M | -$2.73 | 131.45% | -7.51% | $37.70 |
|
PFE
Pfizer Inc.
|
$16.8B | $0.57 | 1.88% | 43.64% | $28.78 |
|
ZTS
Zoetis, Inc.
|
$2.4B | $1.40 | 4.57% | 8.81% | $154.78 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IDXX
IDEXX Laboratories, Inc.
|
$687.74 | $766.00 | $54.9B | 54.52x | $0.00 | 0% | 13.46x |
|
ISRG
Intuitive Surgical, Inc.
|
$522.04 | $611.82 | $185.1B | 66.24x | $0.00 | 0% | 18.81x |
|
LLY
Eli Lilly & Co.
|
$1,023.80 | $1,133.93 | $916.3B | 50.63x | $1.50 | 0.59% | 15.71x |
|
MRNA
Moderna, Inc.
|
$45.30 | $37.70 | $17.7B | -- | $0.00 | 0% | 7.86x |
|
PFE
Pfizer Inc.
|
$25.86 | $28.78 | $147B | 15.07x | $0.43 | 6.65% | 2.35x |
|
ZTS
Zoetis, Inc.
|
$123.92 | $154.78 | $54.6B | 20.88x | $0.53 | 1.64% | 5.89x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IDXX
IDEXX Laboratories, Inc.
|
41.62% | 1.088 | 2.18% | 0.69x |
|
ISRG
Intuitive Surgical, Inc.
|
-- | 1.051 | -- | 3.42x |
|
LLY
Eli Lilly & Co.
|
64.11% | -0.496 | 6.22% | 0.65x |
|
MRNA
Moderna, Inc.
|
7.29% | 0.833 | 7.28% | 3.30x |
|
PFE
Pfizer Inc.
|
39.94% | 0.405 | 42.51% | 0.81x |
|
ZTS
Zoetis, Inc.
|
57.4% | 0.395 | 11.26% | 2.02x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IDXX
IDEXX Laboratories, Inc.
|
$685.3M | $356.8M | 39.29% | 66.88% | 32.28% | $357.9M |
|
ISRG
Intuitive Surgical, Inc.
|
$1.9B | $864.3M | 16.57% | 16.59% | 30.16% | $735.6M |
|
LLY
Eli Lilly & Co.
|
$14.6B | $8.4B | 33.81% | 106.26% | 47.65% | $6B |
|
MRNA
Moderna, Inc.
|
$757M | -$260M | -27.85% | -30.18% | -25.59% | -$880M |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
|
ZTS
Zoetis, Inc.
|
$1.7B | $936M | 22.32% | 52.95% | 39% | $805M |
IDEXX Laboratories, Inc. vs. Competitors
-
Which has Higher Returns IDXX or ISRG?
Intuitive Surgical, Inc. has a net margin of 24.85% compared to IDEXX Laboratories, Inc.'s net margin of 27.89%. IDEXX Laboratories, Inc.'s return on equity of 66.88% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.
Company Gross Margin Earnings Per Share Invested Capital IDXXIDEXX Laboratories, Inc.62.01% $3.40 $2.7B ISRGIntuitive Surgical, Inc.66.56% $2.21 $17.9B -
What do Analysts Say About IDXX or ISRG?
IDEXX Laboratories, Inc. has a consensus price target of $766.00, signalling upside risk potential of 11.38%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $611.82 which suggests that it could grow by 17.2%. Given that Intuitive Surgical, Inc. has higher upside potential than IDEXX Laboratories, Inc., analysts believe Intuitive Surgical, Inc. is more attractive than IDEXX Laboratories, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDXXIDEXX Laboratories, Inc.5 5 1 ISRGIntuitive Surgical, Inc.16 10 1 -
Is IDXX or ISRG More Risky?
IDEXX Laboratories, Inc. has a beta of 1.671, which suggesting that the stock is 67.09% more volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.669, suggesting its more volatile than the S&P 500 by 66.867%.
-
Which is a Better Dividend Stock IDXX or ISRG?
IDEXX Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEXX Laboratories, Inc. pays -- of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDXX or ISRG?
IDEXX Laboratories, Inc. quarterly revenues are $1.1B, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.9B. IDEXX Laboratories, Inc.'s net income of $274.6M is lower than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, IDEXX Laboratories, Inc.'s price-to-earnings ratio is 54.52x while Intuitive Surgical, Inc.'s PE ratio is 66.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories, Inc. is 13.46x versus 18.81x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDXXIDEXX Laboratories, Inc.13.46x 54.52x $1.1B $274.6M ISRGIntuitive Surgical, Inc.18.81x 66.24x $2.9B $799.5M
-
Which has Higher Returns IDXX or LLY?
Eli Lilly & Co. has a net margin of 24.85% compared to IDEXX Laboratories, Inc.'s net margin of 31.72%. IDEXX Laboratories, Inc.'s return on equity of 66.88% beat Eli Lilly & Co.'s return on equity of 106.26%.
Company Gross Margin Earnings Per Share Invested Capital IDXXIDEXX Laboratories, Inc.62.01% $3.40 $2.7B LLYEli Lilly & Co.82.91% $6.21 $66.4B -
What do Analysts Say About IDXX or LLY?
IDEXX Laboratories, Inc. has a consensus price target of $766.00, signalling upside risk potential of 11.38%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,133.93 which suggests that it could grow by 10.76%. Given that IDEXX Laboratories, Inc. has higher upside potential than Eli Lilly & Co., analysts believe IDEXX Laboratories, Inc. is more attractive than Eli Lilly & Co..
Company Buy Ratings Hold Ratings Sell Ratings IDXXIDEXX Laboratories, Inc.5 5 1 LLYEli Lilly & Co.18 7 0 -
Is IDXX or LLY More Risky?
IDEXX Laboratories, Inc. has a beta of 1.671, which suggesting that the stock is 67.09% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.185%.
-
Which is a Better Dividend Stock IDXX or LLY?
IDEXX Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.59% to investors and pays a quarterly dividend of $1.50 per share. IDEXX Laboratories, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios IDXX or LLY?
IDEXX Laboratories, Inc. quarterly revenues are $1.1B, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. IDEXX Laboratories, Inc.'s net income of $274.6M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, IDEXX Laboratories, Inc.'s price-to-earnings ratio is 54.52x while Eli Lilly & Co.'s PE ratio is 50.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories, Inc. is 13.46x versus 15.71x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDXXIDEXX Laboratories, Inc.13.46x 54.52x $1.1B $274.6M LLYEli Lilly & Co.15.71x 50.63x $17.6B $5.6B
-
Which has Higher Returns IDXX or MRNA?
Moderna, Inc. has a net margin of 24.85% compared to IDEXX Laboratories, Inc.'s net margin of -19.69%. IDEXX Laboratories, Inc.'s return on equity of 66.88% beat Moderna, Inc.'s return on equity of -30.18%.
Company Gross Margin Earnings Per Share Invested Capital IDXXIDEXX Laboratories, Inc.62.01% $3.40 $2.7B MRNAModerna, Inc.74.51% -$0.51 $10.1B -
What do Analysts Say About IDXX or MRNA?
IDEXX Laboratories, Inc. has a consensus price target of $766.00, signalling upside risk potential of 11.38%. On the other hand Moderna, Inc. has an analysts' consensus of $37.70 which suggests that it could fall by -16.78%. Given that IDEXX Laboratories, Inc. has higher upside potential than Moderna, Inc., analysts believe IDEXX Laboratories, Inc. is more attractive than Moderna, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDXXIDEXX Laboratories, Inc.5 5 1 MRNAModerna, Inc.2 18 1 -
Is IDXX or MRNA More Risky?
IDEXX Laboratories, Inc. has a beta of 1.671, which suggesting that the stock is 67.09% more volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.170, suggesting its more volatile than the S&P 500 by 16.991%.
-
Which is a Better Dividend Stock IDXX or MRNA?
IDEXX Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEXX Laboratories, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDXX or MRNA?
IDEXX Laboratories, Inc. quarterly revenues are $1.1B, which are larger than Moderna, Inc. quarterly revenues of $1B. IDEXX Laboratories, Inc.'s net income of $274.6M is higher than Moderna, Inc.'s net income of -$200M. Notably, IDEXX Laboratories, Inc.'s price-to-earnings ratio is 54.52x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories, Inc. is 13.46x versus 7.86x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDXXIDEXX Laboratories, Inc.13.46x 54.52x $1.1B $274.6M MRNAModerna, Inc.7.86x -- $1B -$200M
-
Which has Higher Returns IDXX or PFE?
Pfizer Inc. has a net margin of 24.85% compared to IDEXX Laboratories, Inc.'s net margin of 21.32%. IDEXX Laboratories, Inc.'s return on equity of 66.88% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital IDXXIDEXX Laboratories, Inc.62.01% $3.40 $2.7B PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About IDXX or PFE?
IDEXX Laboratories, Inc. has a consensus price target of $766.00, signalling upside risk potential of 11.38%. On the other hand Pfizer Inc. has an analysts' consensus of $28.78 which suggests that it could grow by 11.3%. Given that IDEXX Laboratories, Inc. has higher upside potential than Pfizer Inc., analysts believe IDEXX Laboratories, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDXXIDEXX Laboratories, Inc.5 5 1 PFEPfizer Inc.7 15 1 -
Is IDXX or PFE More Risky?
IDEXX Laboratories, Inc. has a beta of 1.671, which suggesting that the stock is 67.09% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.
-
Which is a Better Dividend Stock IDXX or PFE?
IDEXX Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.65% to investors and pays a quarterly dividend of $0.43 per share. IDEXX Laboratories, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios IDXX or PFE?
IDEXX Laboratories, Inc. quarterly revenues are $1.1B, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. IDEXX Laboratories, Inc.'s net income of $274.6M is lower than Pfizer Inc.'s net income of $3.6B. Notably, IDEXX Laboratories, Inc.'s price-to-earnings ratio is 54.52x while Pfizer Inc.'s PE ratio is 15.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories, Inc. is 13.46x versus 2.35x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDXXIDEXX Laboratories, Inc.13.46x 54.52x $1.1B $274.6M PFEPfizer Inc.2.35x 15.07x $16.7B $3.6B
-
Which has Higher Returns IDXX or ZTS?
Zoetis, Inc. has a net margin of 24.85% compared to IDEXX Laboratories, Inc.'s net margin of 30.04%. IDEXX Laboratories, Inc.'s return on equity of 66.88% beat Zoetis, Inc.'s return on equity of 52.95%.
Company Gross Margin Earnings Per Share Invested Capital IDXXIDEXX Laboratories, Inc.62.01% $3.40 $2.7B ZTSZoetis, Inc.70.21% $1.63 $12.7B -
What do Analysts Say About IDXX or ZTS?
IDEXX Laboratories, Inc. has a consensus price target of $766.00, signalling upside risk potential of 11.38%. On the other hand Zoetis, Inc. has an analysts' consensus of $154.78 which suggests that it could grow by 24.9%. Given that Zoetis, Inc. has higher upside potential than IDEXX Laboratories, Inc., analysts believe Zoetis, Inc. is more attractive than IDEXX Laboratories, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDXXIDEXX Laboratories, Inc.5 5 1 ZTSZoetis, Inc.7 9 0 -
Is IDXX or ZTS More Risky?
IDEXX Laboratories, Inc. has a beta of 1.671, which suggesting that the stock is 67.09% more volatile than S&P 500. In comparison Zoetis, Inc. has a beta of 0.970, suggesting its less volatile than the S&P 500 by 2.953%.
-
Which is a Better Dividend Stock IDXX or ZTS?
IDEXX Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zoetis, Inc. offers a yield of 1.64% to investors and pays a quarterly dividend of $0.53 per share. IDEXX Laboratories, Inc. pays -- of its earnings as a dividend. Zoetis, Inc. pays out 32.86% of its earnings as a dividend. Zoetis, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios IDXX or ZTS?
IDEXX Laboratories, Inc. quarterly revenues are $1.1B, which are smaller than Zoetis, Inc. quarterly revenues of $2.4B. IDEXX Laboratories, Inc.'s net income of $274.6M is lower than Zoetis, Inc.'s net income of $721M. Notably, IDEXX Laboratories, Inc.'s price-to-earnings ratio is 54.52x while Zoetis, Inc.'s PE ratio is 20.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories, Inc. is 13.46x versus 5.89x for Zoetis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDXXIDEXX Laboratories, Inc.13.46x 54.52x $1.1B $274.6M ZTSZoetis, Inc.5.89x 20.88x $2.4B $721M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 65x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
72
BNAI alert for Jan 29
Brand Engagement Network, Inc. [BNAI] is down 16.89% over the past day.
Buy
82
STX alert for Jan 29
Seagate Technology Holdings Plc [STX] is up 0.83% over the past day.
Buy
84
GDXU alert for Jan 29
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 12.19% over the past day.
